Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.
종목 코드 BVS
회사 이름Bioventus Inc
상장일Feb 11, 2021
CEOClaypoole (Robert E)
직원 수930
유형Ordinary Share
회계 연도 종료Feb 11
주소4721 Emperor Boulevard, Suite 100
도시DURHAM
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호27703
전화19194746700
웹사이트https://www.bioventus.com/
종목 코드 BVS
상장일Feb 11, 2021
CEOClaypoole (Robert E)
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음